To confirm the inducing effect of IFN-γ and IL-21 on mTOR activation, p-4EBP expression was next evaluated in duodenal samples of ACD patients treated with antibodies neutralizing IFN-γ or IL-21. The gene discussed is IL21; the disease is granular corneal dystrophy type II.